In Queensland, authorities announced on 4 February 2026 that Dr Michael Byrom—a cardiothoracic surgeon previously restricted by the New South Wales regulator from performing major heart and lung procedures—has been appointed to a senior clinical safety role with Queensland Health. The appointment of Dr Byrom as the inaugural surgical medical lead for Clinical Excellence Queensland, an organisation tasked with driving quality and safety across public health services, has drawn attention to governance and patient-safety considerations across state health services. A Queensland Health spokesperson said the appointment followed a thorough recruitment process, though details about the prior restrictions have not been fully disclosed by the government.
Officials emphasise the role is focused on improving outcomes and reducing harm through governance, data analytics and standardised procedures. Critics are seeking clarity on how someone previously barred from certain operations sits in such a governance position, and whether safeguards exist to guard against conflicts of interest or risk to patient safety. The premier has asked for an investigation into how the appointment came about, and the deputy director general of Clinical Excellence Queensland, Dr Helen Brown, announced the appointment.
What we know
- Dr Michael Byrom has been named the inaugural surgical medical lead for Clinical Excellence Queensland, with a focus on safety, quality and efficiency.
- The appointment was publicly announced by Dr Helen Brown, the deputy director general of Clinical Excellence Queensland.
- Queensland Health describes the recruitment as thorough and says there was a formal process behind the selection.
- The surgeon was previously restricted by the New South Wales medical regulator from performing major heart and lung procedures.
- The arrangement situates the clinician in a role intended to influence clinical governance and safety across the system.
What we don’t know
- The exact details of the previous NSW restrictions, including which operations and when they applied, have not been disclosed.
- How the appointment will balance clinical expertise with safety governance and potential conflicts of interest.
- What safeguards and oversight will govern the new role and how performance will be assessed.
- Whether further inquiries or clarifications will be pursued by politicians or health authorities.
- How this decision will be viewed by the wider medical community and by patients receiving care in Queensland and NSW.
Further questions remain as authorities say they will respond in due course. In the meantime, the case raises broader questions about how health systems assess leadership candidates who have past restrictions and how such decisions align with public safety expectations.
